<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>SARS-CoV-2 Variants of Concern: Omicron sublineages&lt;sup&gt;[1-6]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">SARS-CoV-2 Variants of Concern: Omicron sublineages<sup>[1-6]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">SARS-CoV-2 Variants of Concern: Omicron sublineages<sup>[1-6]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1 border_right_thick border_bottom_thick" rowspan="2">Omicron sublineage<br/> (parent sublineage)</td> <td class="subtitle1" colspan="4">Therapeutic/prophylactic monoclonal antibodies</td> </tr> <tr class="border_bottom_thick"> <td class="subtitle2">Tixagevimab-cilgavimab<br/> (no longer recommended)</td> <td class="subtitle2">Bebtelovimab<br/> (no longer recommended)</td> <td class="subtitle2">Sotrovimab<br/> (no longer recommended)</td> <td class="subtitle2">Casirivimab-imdevimab<br/> (no longer recommended)</td> </tr> <tr> <td class="border_right_thick">BA.1</td> <td><strong>Reduced activity</strong></td> <td><strong>Active</strong></td> <td><strong>Active</strong></td> <td>Inactive</td> </tr> <tr> <td class="border_right_thick">BA.2</td> <td><strong>Active</strong></td> <td><strong>Active</strong></td> <td>Inactive</td> <td>Inactive</td> </tr> <tr> <td class="border_right_thick">BA.4/BA.5</td> <td><strong>Reduced activity</strong></td> <td><strong>Active</strong></td> <td>Inactive</td> <td>Inactive</td> </tr> <tr> <td class="border_right_thick">BA.4.6 (BA.4)</td> <td>Inactive</td> <td><strong>Likely active</strong></td> <td>Inactive</td> <td>Inactive</td> </tr> <tr> <td class="border_right_thick">BA.2.75.2 (BA.2)</td> <td>Inactive*</td> <td><strong>Likely active</strong></td> <td>Inactive</td> <td>Inactive</td> </tr> <tr> <td class="border_right_thick">BQ.1/BQ.1.1 (BA.5)</td> <td>Inactive</td> <td>Inactive</td> <td>Inactive</td> <td>Inactive</td> </tr> <tr> <td class="border_right_thick">XBB/XBB.1/XBB.1.5 (BA.2.10.1 and BA.2.75 recombinant)</td> <td>Inactive</td> <td>Inactive</td> <td>Inactive</td> <td>Inactive</td> </tr> </tbody></table></div><div class="graphic_lgnd"><p>"Variants of Concern" have evidence of an increase in transmissibility, greater risk of severe disease, a significant reduction in neutralization by antibodies generated during previous infection or vaccination, or reduced effectiveness of treatments or vaccines. Since 2022, Omicron (B.1.1.529) variants within evolving sublineages have been the predominant circulating variants globally. Prior Variants of Concern that are no longer circulating are the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) variants.</p>
<p>In the United States, the proportion of circulating variants in each state can be found on the <a href="https://covid.cdc.gov/covid-data-tracker/?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fcases-updates%2Fvariant-proportions.html#variant-proportions" target="_blank">CDC website</a>.</p>
Predicted activity of monoclonal antibodies against various SARS-CoV-2 variants is based on neutralizing assays that use pseudoviruses bearing the key spike protein mutations found in each variant. Neutralizing data are emerging for certain Omicron sublineages and are thus uncertain.</div><div class="graphic_footnotes"><p>CDC: United States Centers for Disease Control and Prevention.</p>
* For a related sublineage, BA.2.75, tixagevimab-cilgavimab appears to retain neutralizing activity.</div><div class="graphic_reference">References:
<ol>
<li>National Institutes of Health. The COVID-19 Treatment Guidelines Panel's Statement on Omicron Subvariants and Anti-SARS-CoV-2 Monoclonal Antibodies. Available at: <a href="https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-omicron-subvariants/" target="_blank">https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-omicron-subvariants/</a> (Accessed on November 9, 2022).</li>
<li>Cao Y, Jian F, Wang J, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. BioRxiv 2022.</li>
<li>Takashita E, Yamayoshi S, Fukushi S, et al. Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75. New Engl J Med 2022; 387:1236.</li>
<li>US Food and Drug Administration. Fact sheet for healthcare providers: Emergency use authorization for bebtelovimab. Available at: <a href="https://www.fda.gov/media/156152/download" target="_blank">https://www.fda.gov/media/156152/download</a> (Accessed on November 9, 2022).</li>
<li>US Food and Drug Administration. FDA Announces Bebtelovimab is Not Currently Authorized in Any US Region. Available at: <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-currently-authorized-any-us-region" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-currently-authorized-any-us-region</a> (Accessed December 1, 2022).</li>
<li>Imai M, Ito M, Kiso M, et al. Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB. New Engl J Med 2023; 388:89.</li>
</ol></div><div id="graphicVersion">Graphic 131216 Version 21.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
